There is provided inter alia a dry power formulation for inhalation comprising: (i) 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin -5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof and solvates thereof in particulate form as active ingredient； (ii) particulate lactose as carrier； and (iii) a particulate stabilizing agent selected from metal salts of stearic acid such as magnesium stearate and metal salts of stearyl fumarate.提供其中用於吸入之乾粉醫藥調配物，其包含：(i)6-(2-((4-胺基-3-(3-羥苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-(2-氯苯甲基)-4-側氧基-3,4-二氫喹唑啉-5-基)-N,N-雙(2-甲氧基乙基)己-5-炔醯胺或其醫藥上可接受鹽，包括所有的立體異構物、互變異構物和其同位素衍生物以及其溶劑化物，其呈微粒形式作為活性成份；(ii)微粒乳糖作為載劑；及(iii)由硬脂酸之金屬鹽類例如硬脂酸鎂，和硬脂醯延胡索酸之金屬鹽類選出之微粒安定劑。
